Context Matters

Context Matters, a health economics data and technology company, delivering solutions to strategically price drugs for reimbursement and optimal market access.

[Context Matters @ContextMatters]

Data derived intelligence on Access to #orphandrugs in the UK: A review of @NICEComms decisions. Presented today at #ISPOREurope #RachelJao

[Context Matters @ContextMatters]

Join us at the @DRGinsights #ISPOREurope2019 booth for some bubbly and sweets this evening! Booth C3-059

[Context Matters @ContextMatters]

Richard Chapman from ICER discusses some of the challenges with evaluating tumor-agnostic therapies. Thank you to all panelists for a fruitful discussion! #HTAi2019 #HTAi2019Cologne

[Context Matters @ContextMatters]

Heading to #HTAi2019Cologne - join us for a discussion with an expert panel on unified vs. localized #HTA systems https://t.co/zXmpMllwfc

[NYC Health Business @NYCHBL]

Make sure to download your copy of the NYC Healthcare venture report! #HCVC2019

[Context Matters @ContextMatters]

Great panel tonight for @NYCHBL Where Will the Money Flow in 2019 #HCVC2019

[Context Matters @ContextMatters]

#startups not seeking input from those they intend to serve is like ignoring #patientvoice in #ClinicalTrials @DataHippie #Data4GoodNY

[Context Matters @ContextMatters]

Is the healthcare system late to the table on #SDOH @DrAlethaMaybank #Data4GoodNY

[Context Matters @ContextMatters]

If we don't engage the private sector in this discussion...how can we move the needle @DataHippie #Data4GoodNY

[Context Matters @ContextMatters]

Community health profiles are powerful tools to improve health and support grant awards @DrAlethaMaybank #Data4GoodNY

[Context Matters @ContextMatters]

In the holiday spirit, @NYCHBL panel discussion Using Data for Good is off to a running start!

[Context Matters @ContextMatters]

Final #ISPORBarcelona workshop had some great audience participation from across the industry and gave us some great ideas on how to increase patient access to #biosimilars in the off-patent biological market.

[Context Matters @ContextMatters]

Third and final plenary of a fantastic #ISPORBarcelona: the need to control spending in healthcare is clear, but the way to do it is less so. Will expenditure caps be the answer or will this lead to worse health outcomes for patients?

[Context Matters @ContextMatters]

Come see three of our oncology posters today on the relationship between QALYs and reimbursement decisions in the UK and managed access agreements under the CDF. Then at 12:15, stop by to ask the authors your questions! #ISPORBarcelona

[Context Matters @ContextMatters]

Ended a great second day at #ISPORBarcelona with a presentation of our poster on the influence of CEESP evaluations on HAS decision making in France.

[Context Matters @ContextMatters]

Heard three great presentations of cost-effectiveness analyses this afternoon: Pembrolizumab and Midostaurin usage in France and oral cancer screening in Taiwan. Shows the diversity of topics we can apply HEOR methods to! #ISPORBarcelona

[Context Matters @ContextMatters]

Thought leadership from CM team member Boaz Adler and @Amgen found that time to reimbursement was shorter for biosimilars than the originator product and the rate of positive reimbursement was higher. #ISPORBarcelona

[Context Matters @ContextMatters]

Big takeaways from the second plenary: Do we need #innovative new treatments? Yes. Do we need new ways to #price innovative treatments? Yes. Do we need new ways to #pay for these treatments? Yes. #ISPORBarcelona

[Context Matters @ContextMatters]

Last session of the day: Dr. Ana Ferreira Castro (even in absentia) reminds us that we need to get the patient perspective in HTAs in order to make sure that the price we are willing to pay for a drug is the right price. #ISPORBarcelona

[Context Matters @ContextMatters]

Drs. Chalkidou, Borowitz and Garner discuss the different needs and perspectives of low, middle and high income countries in price setting and determining drug value using HTA value-based pricing vs. WHO fair pricing. Maybe there is no one size fits all approach? #ISPORBarcelona